[
  {
    "ts": null,
    "headline": "Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)?",
    "summary": "Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent benefits as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma, including those previously considered ineligible for standard high-dose chemotherapy and stem cell transplant. This finding could encourage oncologists to use Yescarta earlier in the treatment pathway, potentially strengthening Gilead’s position in the fast-growing cell...",
    "url": "https://finnhub.io/api/news?id=1fa759a636cf2a0f1698e04a783ffb2063f667938cd56d20a760a081cd0f8455",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765645907,
      "headline": "Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)?",
      "id": 137792583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent benefits as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma, including those previously considered ineligible for standard high-dose chemotherapy and stem cell transplant. This finding could encourage oncologists to use Yescarta earlier in the treatment pathway, potentially strengthening Gilead’s position in the fast-growing cell...",
      "url": "https://finnhub.io/api/news?id=1fa759a636cf2a0f1698e04a783ffb2063f667938cd56d20a760a081cd0f8455"
    }
  }
]